Axsome Therapeutics Acquires Global Rights to Balipodect, a Potential First-in-Class PDE10A Inhibitor

Key Points for Investors

• Axsome Therapeutics (NASDAQ: AXSM) announced the acquisition of exclusive global rights to balipodect (formerly TAK-063), a selective phosphodiesterase 10A (PDE10A) inhibitor from Takeda.
• Balipodect is a novel oral compound with a potentially first-in-class mechanism for treating schizophrenia and Tourette syndrome.
• Axsome intends to initiate Phase 3 trial-enabling activities for schizophrenia in 2026, signaling imminent advancement in clinical development.
• The acquisition further expands Axsome’s CNS pipeline, which already includes several FDA-approved treatments and late-stage programs.
• Balipodect demonstrated favorable safety and tolerability in over 360 individuals, including a completed 164-patient Phase 2 proof-of-concept trial in schizophrenia.
• Takeda will receive upfront payment, milestone payments for the first two indications, and royalties on potential global net sales.

Detailed Analysis

Axsome Therapeutics continues its strategic expansion in the CNS space with the acquisition of balipodect, a highly selective inhibitor of PDE10A. This molecule introduces a potentially first-in-class mechanism of action for the treatment of schizophrenia and Tourette syndrome, both of which represent significant unmet needs and market opportunities in neuropsychiatry.

The deal provides Axsome with exclusive worldwide commercial, development, and manufacturing rights to balipodect. The asset’s clinical profile is promising, as it has already completed a Phase 2 proof-of-concept trial in schizophrenia involving 164 patients. Across all clinical studies, balipodect has been administered to over 360 individuals, showing a favorable safety and tolerability profile. Notably, balipodect did not cause increases in glucose or prolactin levels, which are common metabolic side effects seen with current antipsychotics. This is attributed to the molecule’s selective activity in striatal neurons downstream of dopamine D1 and D2 receptor signaling.

Under the terms of the agreement, Takeda receives an upfront payment and is eligible for additional payments tied to development, regulatory, and commercial milestones for the first two indications, plus royalties on potential global net sales. The financial implications for Axsome include the potential for milestone payments and royalties, which may impact future cash flows depending on clinical and commercial success.

Balipodect’s mechanism targets PDE10A, an enzyme predominantly expressed in medium spiny neurons of the striatum, positioning it as a novel therapeutic option for neuropsychiatric conditions. The lack of metabolic side effects and its activity downstream of dopamine receptors differentiate it from existing antipsychotic drugs.

Schizophrenia affects approximately 3.7 million people in the US and remains one of the leading causes of disability worldwide. Current treatments often fail to address all symptom domains (positive, negative, and cognitive), and carry significant safety and tolerability issues. The addition of balipodect to Axsome’s pipeline could provide a competitive advantage and address critical gaps in schizophrenia treatment.

Axsome’s broader CNS portfolio already includes FDA-approved products for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine. The company is also advancing multiple late-stage programs targeting over 150 million patients in the US suffering from neurological and psychiatric conditions.

Shareholder Considerations & Potential Price Sensitivity

• This acquisition is a material event for Axsome, potentially impacting share value due to the expansion of its pipeline and the imminent Phase 3 development for schizophrenia.
• The market may react positively to the addition of a first-in-class asset with a differentiated safety profile and new mechanism of action.
• Financial terms (milestone payments and royalties) could affect future cash flows, but also represent potential upside if balipodect achieves successful commercialization.
• Investors should monitor upcoming trial initiation and regulatory milestones, as positive clinical data or accelerated timelines may drive stock price movements.
• Any delay or failure in clinical development, regulatory approval, or commercialization could negatively impact share value.

Forward-Looking Statements and Risks

Axsome’s press release includes forward-looking statements regarding the development and commercial prospects of balipodect, anticipated clinical trials, regulatory submissions, and other projections. These statements are subject to risks including, but not limited to, clinical trial success, regulatory approval, market acceptance, payer coverage, intellectual property protection, and unforeseen external factors such as economic conditions or global events.

Contact Information

• Investors: Ashley Dong, Senior Director, Investor Relations, (929) 687-1614, [email protected]
• Media: Darren Opland, Senior Director, Corporate Communications, (929) 837-1065, [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers should conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions related to Axsome Therapeutics, Inc.

View Axsome Therapeutics, Inc. Historical chart here